Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

Mohammad Javad Nasiri, Moein Zangiabadian, Erfan Arabpour, Sirus Amini, Farima Khalili, Rosella Centis, Lia D'Ambrosio, Justin T Denholm, H Simon Schaaf, Martin van den Boom, Xhevat Kurhasani, Margareth Pretti Dalcolmo, Seif Al-Abri, Jeremiah Chakaya, Jan-Willem Alffenaar, Onno Akkerman, Denise Rossato Silva, Marcela Muňoz-Torrico, Barbara Seaworth, Emanuele PontaliLaura Saderi, Simon Tiberi, Alimuddin Zumla, Giovanni Battista Migliori, Giovanni Sotgiu*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

22 Citaten (Scopus)
78 Downloads (Pure)


INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety.

METHODS: We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant.

RESULTS: After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05).

CONCLUSIONS: In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.

Originele taal-2English
Pagina's (van-tot)S90-S103
Aantal pagina's14
TijdschriftInternational Journal of Infectious Diseases
StatusPublished - 1-nov.-2022

Citeer dit